$25.77
-0.17(-0.66%)
Mkt Cap $1.9B
$9.44
$27.62
52-Week Range
At a Glance
AI-generatedRevenue breakdown: License And Milestone Payments (24.9%), Milestone And Other Payments (18.9%), Commercial Sales Milestones (14.9%).
8-K
Zymeworks Inc. appointed Kristin Stafford as Executive Vice President and Chief Financial Officer effective April 1, 2026, succeeding Kenneth Galbraith as interim CFO while he continues as CEO.$1.9B
Market Cap
$105M
Revenue
-$80M
Net Income
Employees299
Fundamentals
How The Business Makes Money
Revenue by Segment
License And Milestone Payments24.9%($1.4B)
Milestone And Other Payments18.9%($1.1B)
Commercial Sales Milestones14.9%($867M)
Commercial Milestones13.8%($803M)
Development Milestone7.3%($424M)
Delivery Of Licenses Initial Technology Transfer And BTC Data Transfer6.5%($375M)
License And Collaboration2.5%($144M)
Milestone Revenue2.4%($137M)
Research Development And Commercial Milestones1.9%($110M)
Upfront Fee1.5%($85M)
Research Support Payments And Other Service1.1%($65M)
Drug Supply For Ongoing Studies0.9%($51M)
Drug Supply0.6%($36M)
Research Milestone0.6%($35M)
Metastatic Castration Resistant Prostate Cancer0.4%($25M)
Performance Milestone0.4%($23M)
Option Exercise Fee0.4%($23M)
Recognition Of Deferred Revenue0.3%($18M)
Deferred Revenue0.3%($18M)
Technology Service0.1%($8M)
Bispecific Antibodies0.1%($8M)
Research And Development Regulatory And Sales Related Milestone0.1%($5M)
Royalty0%($3M)
Research Period Extension Fee0%($250.0K)
Activity
What Changed Recently
Company Profile
CIK0001937653
ISINUS98985Y1082
CUSIP98985W102
Phone16046781388
Address114 East 4th Avenue, Middletown, BC, V5T 1G4, CA
SEC EDGAR